Johnson & Johnson $JNJ Shares Sold by Arvest Bank Trust Division

Arvest Bank Trust Division reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,570 shares of the company’s stock after selling 3,860 shares during the quarter. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $12,460,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson & Johnson in the first quarter valued at approximately $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $195.19 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $196.00. The company has a market cap of $470.27 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The firm has a fifty day moving average of $185.46 and a 200-day moving average of $169.66. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Scotiabank started coverage on Johnson & Johnson in a research report on Thursday. They issued a “sector outperform” rating and a $230.00 price objective on the stock. Raymond James Financial upped their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $200.52.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.